Background/Aims: Dumping syndrome is a common complication in children after fundoplication and other gastric surgeries and is characterized by postprandial hypoglycemia (PPH). Children with PPH have an exaggerated GLP-1 response to a meal with an exaggerated insulin surge and subsequent hypoglycemia. We evaluated the role of GLP-1 in the pathogenesis of PPH by examining the effects of GLP-1 receptor blockade on glucose and insulin response to a meal. Methods: Six children with known PPH after surgery underwent a mixed meal tolerance test with/without the GLP-1 receptor antagonist exendin-(9-39) using an open-label crossover design. Results: Average nadir plasma glucose concentration was ≥65 mg/dl in all treatment conditions; however, 3 out of the 6 subjects had a nadir plasma glucose <65 mg/dl during vehicle infusion, while only 1 out of the 6 had a nadir plasma glucose <65 mg/dl during infusion of exendin-(9-39). Exendin-(9-39) suppressed postmeal insulin concentrations when compared to vehicle, with a lower peak insulin concentration observed in the children who received 500 pmol/kg/min of exendin-(9-39) (131.3 ± 125.1 pmol/l) compared to children who received 300 pmol/kg/min (231.1 ± 153.4 pmol/l) or vehicle (259.7 ± 120.2 pmol/l). Gastric emptying was not different between groups. Conclusion: Our results suggest that the exaggerated insulin response to a meal is at least in part due to the effects of GLP-1 on the pancreatic β-cell and suggest that GLP-1 receptor antagonists may represent a potential avenue of treatment for children with PPH.

Keywords:
Postprandial hypoglycemia, Children, Gastric surgery, Dumping, GLP-1, Exendin-(9–39), Insulin, Fundoplication
1.
Ng DD, Ferry RJJ, Kelly A, Weinzimer SA, Stanley CA, Katz LE: Acarbose treatment of postprandial hypoglycemia in children after Nissen fundoplication. J Pediatr 2001;139:877-879.
2.
Villet R, Boureau M, Hayat P, Weisgerber G: Dumping syndrome, a serious complication of Nissen's operation: a report of four cases (author's translation). Chir Pediatr 1978;19:269-273.
3.
Caulfield ME, Wyllie R, Firor HV, Michener W: Dumping syndrome in children. J Pediatr 1987;110:212-215.
4.
Ralphs DN, Thomson JP, Haynes S, Lawson-Smith C, Hobsley M, Le Quesne LP: The relationship between the rate of gastric emptying and the dumping syndrome. Br J Surg 1978;65:637-641.
5.
Gilger MA, Yeh C, Chiang J, Dietrich C, Brandt ML, El-Serag HB: Outcomes of surgical fundoplication in children. Clin Gastroenterol Hepatol 2004;2:978-984.
6.
Fonkalsrud EW, Ashcraft KW, Coran AG, Ellis DG, Grosfeld JL, Tunell WP, Weber TR: Surgical treatment of gastroesophageal reflux in children: a combined hospital study of 7467 patients. Pediatrics 1998;101:419-422.
7.
Bufler P, Ehringhaus C, Koletzko S: Dumping syndrome: a common problem following Nissen fundoplication in young children. Pediatr Surg Int 2001;17:351-355.
8.
Samuk I, Afriat R, Horne T, Bistritzer TJB, Vinograd I: Dumping syndrome following Nissen fundoplication, diagnosis, and treatment. J Pediatr Gastroenterol Nutr 1996;23:235-240.
9.
Calabria AC, Gallagher PR, Simmons R, Blinman T, De Leon DD: Postoperative surveillance and detection of postprandial hypoglycemia after fundoplasty in children. J Pediatr 2011;159:597-601 e591.
10.
Palladino AA, Sayed S, Katz LE, Gallagher PR, De Leon DD: Increased glucagon-like peptide-1 secretion and postprandial hypoglycemia in children after Nissen fundoplication. J Clin Endocrinol Metab 2009;94:39-44.
11.
Drucker DJ: Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002;122:531-544.
12.
MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB: The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002;51(suppl 3):S434-S442.
13.
Holst JJ: Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002;18:430-441.
14.
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycemia by exogenous glucagon-like peptide-1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-744.
15.
Orskov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptide-1 (proglucagon 78-107 amide) on endocrine secretion from pig pancreas, antrum and stomach. Endocrinology 1988;123:2009-2013.
16.
Hvidberg A, Nielsen M-B, Hilsted J, Orskov C, Holst JJ: Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism 1994;43:104-108.
17.
Larsson H, Holst JJ, Ahren B: Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997;160:413-422.
18.
Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (Proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-673.
19.
Willms B, Wermer J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327-332.
20.
Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-520.
21.
Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C: Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541-R1544.
22.
Smith EP, An Z, Wagner C, Lewis AG, Cohen EB, Li B, Mahbod P, Sandoval D, Perez-Tilve D, Tamarina N, et al: The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab 2014;19:1050-1057.
23.
Salehi M, Prigeon RL, D'Alessio DA: Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 2011;60:2308-2314.
24.
Salehi M, Gastaldelli A, D'Alessio DA: Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology 2014;146:669-680 e662.
25.
Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M: Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998;101:1421-1430.
26.
Calabria AC, Li C, Gallagher PR, Stanley CA, De Leon DD: GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel. Diabetes 2012;61:2585-2591.
27.
Willems M, Quartero AO, Numans ME: How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci 2001;46:2256-2262.
28.
Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR: Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999;48:86-93.
29.
Borovoy J, Furuta L, Nurko S: Benefit of uncooked cornstarch in the management of children with dumping syndrome fed exclusively by gastrostomy. Am J Gastroenterol 1998;93:814-818.
30.
Lehnert H, Beyer J, Weber P, Krause U, Schrezenmeir J: Treatment of severe reactive hypoglycemia with a somatostatin analogue (SMS 201-995). Arch Intern Med 1990;150:2401-2402.
31.
Khoshoo V, Reifen RM, Gold BD, Sherman PM, Pencharz PB: Nutritional manipulation in the management of dumping syndrome. Arch Dis Child 1991;66:1447-1448.
32.
Buscemi S, Mattina A, Genova G, Genova P, Nardi E, Costanzo M: Seven-day subcutaneous continuous glucose monitoring demonstrates that treatment with acarbose attenuates late dumping syndrome in a woman with gastrectomy for gastric cancer. Diabetes Res Clin Pract 2013;99:e1-e2.
33.
Ritz P, Vaurs C, Bertrand M, Anduze Y, Guillaume E, Hanaire H: Usefulness of acarbose and dietary modifications to limit glycemic variability following Roux-en-Y gastric bypass as assessed by continuous glucose monitoring. Diabetes Technol Ther 2012;14:736-740.
34.
Hanaire H, Dubet A, Chauveau ME, Anduze Y, Fernandes M, Melki V, Ritz P: Usefulness of continuous glucose monitoring for the diagnosis of hypoglycemia after a gastric bypass in a patient previously treated for type 2 diabetes. Obes Surg 2010;20:126-129.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.